



# THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **Sale-based estimation of pharmaceutical concentrations and associated environmental risk in the Japanese wastewater system**

**Citation for published version:**

He, K, Borthwick, A, Lin, Y & Li, Y 2020, 'Sale-based estimation of pharmaceutical concentrations and associated environmental risk in the Japanese wastewater system', *Environment International*.  
<https://doi.org/10.1016/j.envint.2020.105690>

**Digital Object Identifier (DOI):**

[10.1016/j.envint.2020.105690](https://doi.org/10.1016/j.envint.2020.105690)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

Environment International

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.





## Sale-based estimation of pharmaceutical concentrations and associated environmental risk in the Japanese wastewater system

Kai He<sup>a</sup>, Alistair G. Borthwick<sup>b</sup>, Yingchao Lin<sup>c,\*</sup>, Yuening Li<sup>c</sup>, Jie Fu<sup>d</sup>, Yongjie Wong<sup>a</sup>, Wen Liu<sup>e,f,\*</sup>

<sup>a</sup> Research Centre for Environmental Quality Management, Kyoto University, 1-2 Yumihama, Otsu, Shiga 520-0811, Japan

<sup>b</sup> Institute for Infrastructure and Environment, School of Engineering, University of Edinburgh, The King's Buildings, EH9 3JL Edinburgh, United Kingdom

<sup>c</sup> College of Environmental Science and Engineering, Ministry of Education Key Laboratory of Pollution Processes and Environmental Criteria, Nankai University, Tianjin 300071, PR China

<sup>d</sup> School of Environmental Science and Engineering, Huazhong University of Science and Technology, Wuhan 430074, PR China

<sup>e</sup> The Key Laboratory of Water and Sediment Sciences, Ministry of Education; Department of Environmental Engineering, Peking University, Beijing 100871, PR China

<sup>f</sup> The Beijing Innovation Center for Engineering Science and Advanced Technology (BIC-ESAT), Peking University, Beijing 100871, PR China

### ARTICLE INFO

Handling Editor: Guo-ping Sheng

#### Keywords:

Pharmaceuticals  
Wastewater system  
Predicted environmental concentrations  
Environmental risk assessment  
EPI suite

### ABSTRACT

Information on sales and emission of selected pharmaceuticals were used to predict their concentrations in Japanese wastewater influent through a > 300 of pharmaceuticals data sink. A combined wastewater-based epidemiology and environmental risk analysis follow was established. By comparing predicted environmental concentrations (PECs) of pharmaceuticals in wastewater influent against measured environmental concentrations (MECs) reported in previous studies, it was found that the model gave accurate results for 17 pharmaceuticals ( $0.5 < \text{PEC}/\text{MEC} < 2$ ), and acceptable results for 32 out of 40 pharmaceuticals ( $0.1 < \text{PEC}/\text{MEC} < 10$ ). Although the majority of pharmaceuticals considered in the model were antibiotics and analgesics, pranlukast, a receptor antagonist, was predicted to have the highest concentration in wastewater influent. With regard to the composition of wastewater effluent, the Estimation Program Interface (EPI) suite was used to predict pharmaceutical removal through activated sludge treatment. Although the performance of the EPI suite was variable in terms of accurate prediction of the removal of different pharmaceuticals, it could be an efficient tool in practice for predicting removal under extreme scenarios. By using the EPI suite with input data on PEC in the wastewater influent, the PEC values of pharmaceuticals in wastewater effluent were predicted. The concentrations of 26 pharmaceuticals were relatively high ( $> 1 \mu\text{g}/\text{L}$ ), and the PECs of 6 pharmaceuticals were extremely high ( $> 10 \mu\text{g}/\text{L}$ ) in wastewater effluent, which could be attributed to their high usage rates by consumers and poor removal rates in wastewater treatment plants (WWTPs). Furthermore, environmental risk assessment (ERA) was carried out by calculating the ratio of predicted no effect concentration (PNEC) to PEC of different pharmaceuticals, and it was found that 9 pharmaceuticals were likely to have high toxicity, and 54 pharmaceuticals were likely to have potential toxicity. It is recommended that this is further investigated in detail. The priority screening and environmental risk assessment results on pharmaceuticals can provide reliable basis for policy-making and environmental management.

### 1. Introduction

Pharmaceuticals are contaminants of emerging concern due to their potential threat to the aquatic ecosystem and human health (Boxall et al., 2012; Ebele et al., 2017; Schwarzenbach et al., 2006). Pharmaceuticals comprise a large, diverse group of compounds, including antibiotics, hormones, anti-inflammatory drugs, antiepileptic drugs, blood lipid regulators,  $\beta$ -blockers, contrast media, and cytostatic drugs

(Mehrabad et al., 2016). Effluent from wastewater treatment plants (WWTPs) is the main source of pharmaceuticals released into the environment (Daughton and Ternes 1999), and reported pharmaceutical concentrations in wastewater treatment systems range from ng/L to  $\mu\text{g}/\text{L}$  (Verlicchi et al., 2012). Due to their limited removal efficiency by conventional wastewater treatment processes, a large number of residual pharmaceuticals are discharged from WWTPs, and contaminate receiving water bodies. According to previous studies, diclofenac was

\* Corresponding authors at: The Key Laboratory of Water and Sediment Sciences, Ministry of Education; Department of Environmental Engineering, Peking University, Beijing 100871, PR China (W. Liu).

E-mail addresses: [dei@nankai.edu.cn](mailto:dei@nankai.edu.cn) (Y. Lin), [wen.liu@pku.edu.cn](mailto:wen.liu@pku.edu.cn) (W. Liu).

<https://doi.org/10.1016/j.envint.2020.105690>

Received 3 November 2019; Received in revised form 27 February 2020; Accepted 24 March 2020

Available online 08 April 2020

0160-4120/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

widely detected in aquatic environments around the world, and it was indicated to have high environmental risk in aquatic environments as well as ethinylestradiol and atorvastatin (Singh et al., 2019; Zhou et al., 2019). Besides, given that many drinking water treatment plants (DWTPs) use source water impacted by wastewater, a possible health risk may exist in drinking water contaminated with pharmaceuticals and personal care products (PPCPs) (Benotti et al., 2008). Traces of pharmaceutical pollution have been found in Canada, Germany, Italy, UK, and the USA (Jones et al., 2005; Zwiener, 2007). Therefore, monitoring pharmaceuticals in wastewater is of vital importance in identifying (and hence addressing) both environmental risk and human risk.

Highly sensitive analytical techniques, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), are used to monitor pharmaceutical concentrations in wastewater. Determination of all pharmaceuticals in a wastewater sample is necessary to estimate accurately the overall risk due to their presence. However, this involves complex pretreatment, expensive operating costs, and lengthy analysis (Petrović et al., 2005), which suggests that a method based on selected, priority pharmaceuticals in wastewater would be beneficial to screen the priority of pharmaceuticals considering the environmental risk. Moreover, Ottmar et al. found that cited scientific research had not considered prescription frequency or daily load, indicating a gap in understanding of the actual situation of pharmaceutical pollution (Ottmar et al., 2010). Thus, a comprehensive strategy for evaluation of priority pharmaceuticals in wastewater is necessary to restrict monitoring to a limited number of the most hazardous drugs. Several studies have estimated the predicted environmental concentration (PEC) of pharmaceuticals in receiving water in order to determine their priority order. For example, the average consumption of paracetamol and metformin, the most commonly prescribed pharmaceuticals in the UK, was used to predict their environmental concentrations of 11.96 and 6.30 µg/L, respectively (Jones et al., 2002). In China, 13 pharmaceuticals were classified as priority pharmaceuticals based on available consumption data (Li et al., 2019). Gómez-Canela et al. prioritized the occurrence of pharmaceuticals in rivers in Catalonia according to pharmaceutical consumption data (Gómez-Canela et al., 2019).

In calculating the PEC of pharmaceuticals in receiving water, three relevant factors should be considered: pharmaceutical consumption, excretion rate, and the removal efficiency of WWTPs. Pharmaceutical consumption is calculated from data on the sales of pharmaceuticals, obtained from medical authorities. In practice, when pharmaceuticals are excreted after metabolism, a variety of metabolites enter the wastewater sewage system together with their parent compounds in urine and feces. Hence, it is necessary to consider the excretion efficiencies by which PECs become refined, i.e., the percentage of the drug excreted with respect to its parent compound. To date, the PEC of pharmaceuticals in effluent has been investigated using factors related to consumption and measured removal efficiencies in target WWTPs (Alder et al., 2010). The occurrence of pharmaceuticals in surface waters has also been evaluated, with the results showing that concentrations of pharmaceuticals correlated well with consumption data (Scheurer et al., 2009; ter Laak et al., 2010). The findings indicate that, among other criteria, international or national sales data can be a valuable resource from which to select relevant pharmaceuticals for monitoring and hence to estimate loads and average environmental concentrations in wastewater. In Japan, the occurrence of pharmaceuticals in the wastewater system has been evaluated in previous studies, in particular during the period from 2007 to 2009, when analgesics (i.e., acetaminophen) and antibiotics (i.e., ampicillin) were detected at high concentrations (Kim et al., 2009; Kobayashi et al., 2006; Nakada et al., 2007; Narumiya et al., 2009). Two prediction studies of pharmaceuticals in wastewater have been performed in Japan (Azuma et al., 2015; Suzuki, 2012), with estimated concentrations of 15 and 7 pharmaceuticals respectively; in both cases, the number of target pharmaceuticals was limited. Obviously, more pharmaceuticals should be selected to enhance accurate prediction in Japan.

Previous studies mainly focused on the well-investigated pharmaceuticals, while the priority of some important but high environmental risk pharmaceuticals could be ignored, and these compounds were carefully investigated in this study. Moreover, a huge data source including > 300 pharmaceuticals with different varieties in pharmacologic classification were applied, and a great many information of these pharmaceuticals were provided for calculation. Furthermore, a novel analysis work flow integrating wastewater-based epidemiology and environmental risk was established, which was from sale data of pharmaceuticals, to their environmental risks, and then to screening the priority of pharmaceuticals. The overall aim of this study is to develop a predictive approach to estimate pharmaceutical concentrations in the Japanese wastewater system by using pharmaceutical industrial sales data and to apply this approach to assess the environmental risk of pharmaceutical contamination. First, an updated list of priority pharmaceuticals was obtained in terms of sales volume, and their PECs in wastewater influent were estimated with respect to excretion rate from the human body and compared against measured environmental concentrations (MECs). Second, after evaluating the feasibility of removal by comparing reported and predicted removal efficiencies of pharmaceuticals in WWTPs, the predicted concentrations of PPCPs in wastewater effluent were estimated. Finally, the environmental risks posed by different pharmaceuticals were evaluated from their PECs in wastewater systems, and priority pharmaceuticals proposed in terms of environmental risk.

## 2. Methods

### 2.1. Pharmaceutical discharge loads

Discharge loads of pharmaceuticals in wastewater were calculated from sales data on pharmaceuticals in Japan, based on the sale yield of pharmaceuticals rather than usage by patients. Sales volumes of over-the-counter drug (OTC) pharmaceuticals in terms of numbers of packs sold per year were obtained from statistics compiled by Japanese Ministry of Health, Labour and Welfare in 2014, which was public from 2017 (Ministry of Health, Labour and Welfare, 2018). Although the local sale data could improve the prediction performance locally, the national sale data can provide the priority pharmaceuticals from the perspective of national policymaking. In addition, the yearly change of pharmaceutical consumption and the consumption behavior of pharmaceuticals in Japanese local area were shown in Figs. S1 and S2, indicating that Japan has relatively stable pharmaceutical consumption in time and space. Furthermore, the concentration of pharmaceutical in wastewater influent was strongly related to the water consumption. The average water consumption in Japan was approximately 300 L per capita, per day with the range of 267 (lowest)–338 (highest) L per capita, per day, which indicated the water consumption fluctuated around 10%. Thus, the national sale data were applied in this study.

### 2.2. PECs of pharmaceuticals in wastewater influent

Following European Medicines Agency (EMA) guidelines (Huschek et al., 2004), PECs in wastewater influent ( $PEC_{inf, EMA}$ ) were estimated from per capita annual consumption in Japan using the following formula:

$$PEC_{inf, EMA} = \frac{A}{365 \times P \times V} \quad (1)$$

where  $A$  is the annual sale amount of pharmaceuticals in Japan (kg per year),  $P$  is the population in the area, and  $V$  is the volume of wastewater per capita, per day ( $0.3 \text{ m}^3$ ) (Ministry of Economy Trade and Industry, Japan, 2010; Ogawa 2006). The population ( $P$ ) in Japan was set as 125,583,658, according to the Japanese government report (Statistics Bureau of Japan, 2017). However, this formula does not consider the influence of the excretion rate. To improve the predictions, the effect of

excretion efficiencies ( $f$ ) of pharmaceuticals from humans was incorporated in the calculation of PEC in the influent ( $PEC_{inf}$ ), indicating the actual amount of active substances entering the sewage system:

$$PEC_{inf} = \frac{A}{365 \times P \times V} \times f \quad (2)$$

Data on renal excretion efficiencies of humans were obtained from the Pharmaceuticals and Medical Devices Agency, Japan (Pharmaceuticals and Medical Devices Agency, 2019), the Japan Pharmaceutical Information Center (Japan Pharmaceutical Information Center, 2004), the KEGG (Kyoto Encyclopedia of Genes and Genomes) database (Kanehisa et al., 2016), Drugbank (Wishart et al., 2017), and previous studies (National Information Program on Antibiotics, 2016; Down et al., 1974; Furuta et al., 2002; Green et al., 2015; Gregory et al., 1993; Naito and Yoshikawa 2010; Rhee et al., 2013; Sakashita et al., 1993; Spratto and Woods 2010; Teramoto et al., 2013; Wang et al., 2012). The details of excretion efficiencies were presented in Supplementary material. Given the variation in the reported values of excretion efficiency, we selected the highest value to account for the most extreme case. For those pharmaceuticals where excretion efficiencies could not be found in databases or the open literature, we set the excretion efficiency to 100% for the most extreme case. In Japan, the average retention time of wastewater in sewage system is generally less than 6 h (Kanagawa Sewerage Work Foundation, 2019), indicating that the pharmaceuticals and their metabolites can be degraded in the WWTPs with relatively short time, so the transformation of pharmaceuticals can be expected in WWTPs.

To clearly illustrate the calculation of  $PEC_{inf}$ , the example of sulphiride was provided as follows: Firstly, the sale of sulphiride was calculated by the sale data of commercially available tablets and capsules including 26,795,000 tablets of 100 mg, 373,075,000 tablets of 50 mg and 28,795,000 capsules of 50 mg (Ministry of Health, Labour and Welfare, 2018), indicating that the total yearly amount of sulphiride in Japan was 22,773 kg; Secondly, the excretion efficiencies of sulphiride was 70%, indicating the excreted amount of sulphiride was 15,941 kg; Thirdly, the concentration was calculated by excreted amount, water consumption, and population as shown in Equation (2), so the  $PEC_{inf}$  of sulphiride was calculated to be 1159.23 ng/L.

In evaluating model performance, the ratio of PEC to MEC was used to establish whether the prediction underestimated or overestimated the concentration of each pharmaceutical (Verlicchi et al., 2014). The values of MECs in wastewater influent were obtained from previous studies (Azuma et al., 2015, 2016; Kobayashi et al., 2006; Nakada et al., 2007; Narumiya et al., 2009; Suzuki, 2012), and the average concentration of the individual pharmaceutical in several previous studies was used as MEC value in this study. An important influence factor is the difference between reported and actual consumption (Oosterhuis et al., 2013), which could be enhanced by the incomplete use of sold pharmaceuticals and pharmaceuticals obtained from other sources (Ruhoy and Daughton, 2008). In addition, the temporal consumption behavior of pharmaceuticals also influences model predictions (You et al., 2015). Researchers have therefore employed certain criteria related to PEC/MEC to evaluate the prediction results. For example, Morasch et al. and Tauxe-Wuersch et al. adopted the following criteria to classify PEC:  $0.1 < PEC/MEC < 10$ , acceptable (Morasch et al., 2010; Tauxe-Wuersch et al., 2005);  $PEC/MEC < 0.1$ , unacceptably low;  $PEC/MEC > 10$ , unacceptably high. Stricter criteria were proposed by Ort et al.:  $0.5 < PEC/MEC < 2$ , acceptable,  $PEC/MEC < 0.5$ , unacceptably low; and  $PEC/MEC > 2$ , unacceptably high (Ort et al., 2009). Table 1 lists the criteria used in the present study in order to classify PEC.

### 2.3. PECs of pharmaceuticals in wastewater effluent

Pharmaceutical concentrations in wastewater influent indicate consumption habits in the study area, and the environmental risk posed

**Table 1**  
Criteria used to classify PEC.

PEC evaluation	PEC/MEC ratio
Unacceptably high	$PEC/MEC > 10$
Acceptably high	$2 < PEC/MEC < 10$
Accurate	$0.5 < PEC/MEC < 2$
Acceptably low	$0.1 < PEC/MEC < 0.5$
Unacceptably low	$PEC/MEC < 0.1$

by pharmaceuticals in receiving water relates to their concentrations in wastewater effluent, which are in turn strongly correlated to the removal performance of WWTPs. In practice, activated sludge is the most prevalent treatment technology in WWTPs in Japan (Japan Sewage Works Association, 2016), and so was taken to be the target process in the present study. First, concentrations of pharmaceuticals in the influent and the effluent of Japanese WWTPs that use the activated sludge process based on previous studies were collated (Azuma et al., 2015; Kobayashi et al., 2006; Nakada et al., 2007; Narumiya et al., 2009; Suzuki, 2012), and the measured removal efficiencies were then calculated. Predicted removal efficiencies of pharmaceuticals in activated sludge were computed using the STP script program in the US EPA's Estimation Program Interface (EPI) Suite that is widely used to predict physicochemical properties and removal efficiencies of target contaminants in WWTPs (Lu et al., 2019; Lu et al., 2017). This STP script program provided the removal prediction in WWTPs based on the typical activated sludge conditions. Although parameters in this script program can be set for prediction, such as half-lives in the primary clarifier, aeration vessel and setting tank, the output of BIOWIN script in EPI suite and EPA draft method was used in this study. Model performance was evaluated by comparing predicted and reported removal efficiencies. In the STP script, the BIOWIN output and the EPA draft method for assigning half-lives were used to predict biodegradation and sorption in activated sludge. In order to evaluate the performance of predicted removal efficiencies by EPI Suite, the criteria of removal efficiencies was referred to Table 1.

The PEC of each pharmaceutical in the wastewater effluent was calculated from:

$$PEC_{eff} = PEC_{inf} \times R \quad (3)$$

where  $R$  is the removal efficiency predicted by the EPI suite.

### 2.4. Environmental risk assessment

Pharmaceutical toxicity data were collected from simulated values obtained using ECOSAR developed by US EPA (Sanderson and Thomsen, 2007), and the KASHINHOU Tool for Ecotoxicity (KATE), an ecotoxicity prediction system based on quantitative structure-activity relationship (QSAR) models with log  $P$  (Furuhashi et al., 2011; Melnikov et al., 2016), developed by the Center for Health and Environmental Risk Research (CHERR) of the National Institute for Environmental Studies (NIES), Japan. No-observed effect concentration (NOEC) and effective concentration (EC) (possessing a given percentage effect, generally 50% effect or EC50) values were compared and the lowest value divided by an appropriate assessment factor (10) to give the predicted no-effect concentration (PNEC) (Caldwell et al., 2019). Referring to previous studies (Ma et al., 2016; Zeng et al., 2018), the toxicity was divided into 4 levels with respect to the ratio  $R_t = MEC/PNEC$  as follows: high risk ( $R_t > 1$ ), medium risk ( $0.1 < R_t < 1$ ), low risk ( $0.01 < R_t < 0.1$ ), and no risk ( $R_t < 0.01$ ).

## 3. Results and discussion

### 3.1. Evaluation of PECs with MECs in wastewater influent

Table S1 in Supplementary material lists the measured and




Fig. 1. Comparison between predicted  $PEC_{inf}$  and measured  $MEC_{inf}$  in wastewater influent.

predicted environmental concentrations of pharmaceuticals in wastewater influent. Fig. 1 is a scatter plot comparing the predicted and measured environmental concentrations of the selected compounds from which it can be readily seen that the predictions of most of the pharmaceutical PECs are acceptable. The correlation coefficient of the logarithmic relationship between the PEC and MEC values is 0.52, indicating the feasibility of the concentration prediction method based on pharmaceutical consumption. Based on the evaluation criteria listed in Table 1, we found that 32 out of 40 (80.0%) reported pharmaceutical PECs were acceptable, and 17 out of 40 (42.5%) pharmaceuticals had accurate PECs, including aspirin (0.86) and disopyramide (1.18). Similar trends were observed in the work by Coetsier et al. who reported that predicted data were acceptable in 36% of cases considered (11 pharmaceuticals) (Coetsier et al., 2009). Metcalfe et al. compared the PEC and MEC of four  $\beta$ -blockers, and found that they had obtained acceptable data at 44% of their sampling points (Metcalfe et al., 2008). The high level of acceptable predictions made by the present study may be attributed to high sewage coverage (78.8%, the ratio of population served by the sewage system to the total population, expressed as a percentage) (Japan Sewage Works Association, 2019) and the high usage of separate sewage systems in Japan. Differences between PECs and MECs could be attributed to the discharge of pharmaceuticals in the wastewater system and consumption from illegal sources (i.e. clandestine manufacturing of pharmaceuticals). Thus, by basing the prediction method on pharmaceutical sales rather than consumption, factors such as unexpected data (i.e. pharmaceuticals distributed without prescription or via hospitals) were avoided (Winker et al., 2008). It should be noted however that Ort et al. observed that national consumption figures do not take into account drugs dispensed to public hospital inpatients departments (Ort et al., 2010); this source of inaccuracy could affect the present study. In addition, transformation of pharmaceuticals by the retention in sewage and temporal variations in pharmaceutical consumption would contribute to the discrepancies between sales and influent concentrations (ter Laak et al., 2010; Oosterhuis et al., 2013). Moreover, national sales data could be inaccurate if local consumption patterns differ from those reported in the national sales data. Hence, we recommend the use of regional consumption data instead of national data if different consumption patterns are expected. Even though the collection and analysis of regional data are potentially difficult tasks, big data technology could facilitate the future direction of such pharmaceutical retrospective approaches. Overall, based on the results in Table S1 and Fig. 1, the foregoing work has resulted in an acceptable tool for the prediction of pharmaceutical concentrations based on sale information, which will be used for the PEC calculation in the following section.

### 3.1.1. Analgesics/anti-inflammatories

Of the reported pharmaceuticals in Japan, analgesics/anti-inflammatories (i.e., acetaminophen, salicylic acid, and salicylamide) are abundant in wastewater influent ( $> 100$  ng/L) (Azuma et al., 2019a,b; Hanamoto et al., 2018; Narumiya et al., 2009). Other studies on the occurrence of pharmaceuticals in wastewater influent (i.e., United States and China) have reported similar findings (Kostich et al., 2014; Liu and Wong, 2013). Azuma et al. detected loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID), at high concentration of 5.663  $\mu$ g/L in wastewater influent (Azuma et al., 2016); this value was similar to the PEC of 5.313  $\mu$ g/L, with PEC/MEC of 0.94. Among analgesics, besides loxoprofen, the PECs of aspirin and disopyramide were also found to be accurately predicted with PEC/MEC of 0.86 and 1.18, respectively. The PEC values for ibuprofen, naproxen, and ketoprofen were acceptably low ( $0.1 < PEC/MEC < 0.5$ ). Acetaminophen is a traditional analgesic/anti-inflammatory commonly used worldwide, and widely detected at relatively high concentrations in wastewater influent (Burns et al., 2018; Du et al., 2014). However, acetaminophen exhibited a significant difference between its PEC (593 ng/L) and its MEC (9594 ng/L). Similarly, mefenamic acid showed considerable difference in its PEC and MEC values, with PEC/MEC = 0.03. The PECs of acetaminophen and mefenamic acid were unacceptably low. Overall, although the PECs of most analgesics/anti-inflammatories were acceptable, their PEC values were lower than their MEC values in the wastewater influent. For analgesics/anti-inflammatories, which are traditional household pharmaceuticals, their improper disposal (i.e., by flushing them down into the sewage system or discarding them with household waste) increased MEC in wastewater influent and disrupted the model prediction accuracy (Mankes and Silver, 2013). In this case, the analgesics/anti-inflammatories bypassed human metabolism, contributing to the high MEC of analgesics/inflammatories in wastewater influent.

### 3.1.2. Antibiotics

Antibiotics are another abundant group of pharmaceuticals found in wastewater influent (Guerra et al., 2014). For example, clarithromycin and levofloxacin have been detected at high concentrations ( $> 400$  ng/L) (Hanamoto et al., 2018; Narumiya et al., 2009). For macrolide antibiotics, such as clarithromycin, roxithromycin, and azithromycin, their predicted influent concentrations are close to the measured values (with PEC/MEC ranging from 0.66 to 2.09), confirming that both the consumption pattern and excretion factor are properly modeled. In addition to macrolide antibiotics, PECs of sulfamethoxazole, thiamphenicol, and trimethoprim were found to be accurate, with PEC/MEC ratios of 1.51, 1.54, and 1.40, respectively. Furthermore, the PEC/MEC ratio of ampicillin was 9.47, indicating an acceptably high PEC in wastewater influent. Ampicillin is a common  $\beta$ -lactam antibiotic used to prevent and treat bacterial infections; the hydrolysis of  $\beta$ -lactam antibiotics has been reported in wastewater (Mitchell et al., 2014). Once ampicillin is excreted into the sewage system, its effective hydrolysis could contribute to its elimination, thus affecting the accuracy of the PEC. For ofloxacin (excretion rate of 64%) (Dave and Morris, 2016), the PEC value in wastewater influent was far lower than the measured concentration (PEC/MEC  $< 0.1$ ), indicating that some other sources of contamination had not been considered in the prediction method. For example, improper disposal or unregistered sources (veterinary medicine), as mentioned previously, could contribute to an increased MEC in wastewater influent.

### 3.1.3. Receptor antagonists/blockers

In addition to analgesics/anti-inflammatories and antibiotics, antagonists are another important group of pharmaceuticals. In the present study, diphenhydramine, sulpiride, atenolol, and pirenzepine were detected at concentrations of 1530.0, 1234.3, 364.3, and 40.5 ng/L, with corresponding PEC/MEC ratios of 0.10, 0.94, 1.17, and 0.75, indicating their PECs in wastewater were acceptable. The results are

consistent with those reported by Metcalfe et al. (Metcalfe et al., 2008). The stability of these pharmaceuticals in sewer systems is likely to have contributed to their acceptable prediction (Phung et al., 2017).

#### 3.1.4. Others

For other reported pharmaceuticals, the PEC values of amantadine (anti-Parkinson), carbamazepine (anticonvulsant), dipyrindamole (anti-thrombotic), and bezafibrate (antilipemic) in wastewater influent are close to the measured ones, and the ratios of PEC/MEC were 1.22, 1.35, 0.80, and 1.87, respectively. These pharmaceuticals are drugs for treating specific diseases, and they are strictly controlled by government agencies, implying that their consumption is strongly related to their reported sales. In addition, their stability in sewage (i.e., poor biodegradability of carbamazepine and its metabolites) can reduce the influence of sewers on concentration prediction. Thus, the consumption pattern and excretion efficiencies adopted in the calculation could be considered acceptable for their prediction in wastewater influent.

### 3.2. Prioritization of pharmaceuticals in wastewater influent

Chemical analysis of exogenous biomarkers of drug consumption in wastewater has been shown to have promise for studying drug use within a defined population (Thomas and Reid, 2011). For example, Ong et al. demonstrated through the use of target pharmaceuticals in wastewater plants that the major groups in Australia are heart medications and statins (lipid-lowering agents) (Ong et al., 2018). Considering the environmental risk of priority pharmaceuticals, an approximation using a calculation method would be very helpful. Hence, the PECs were estimated of pharmaceuticals listed in the Japanese Annual Report on Pharmaceutical Industries (Ministry of Health, Labour and Welfare, Japan, 2018), and a reverse analysis developed of wastewater based on epidemiology (using the prediction model described previously). As shown in Fig. 2, for pharmaceutical yearly sales, antiallergic, analgesic, digestive, and antibiotic pharmaceuticals were dominant. Although excretion efficiencies vary with different pharmaceuticals, analgesics and psychotropics have low excretion efficiencies, indicating their possible lower priority in wastewater influent despite their higher sales data.

As shown in Table S2, pranlukast and carbocysteine are pharmaceuticals consumed in the greatest quantities, with 4080.3 t and 1372.6 t consumed per year, respectively. These high consumption levels could be attributed to the fact that Japan was the first country in the world to introduce pranlukast to the market for the treatment of bronchial asthma (Suissa and Ernst, 2003), and that the Japanese market has promoted use of carbocysteine as a well-known mucocactive and mucoregulatory drug (Ishiura et al., 2003). Moreover, the prevalence of asthma in Japan has been reportedly increasing (Fukutomi et al., 2011). The significant consumption of antagonist, mucolytic, and hypoglycemic pharmaceuticals is due to the aging population in Japan. Carballa et al. reported that the pharmaceutical consumed in the highest amount in Spain was ibuprofen (276.1 tons), and compared annual per capita consumption of 17 pharmaceuticals in different countries (Carballa et al., 2008). Ottmar et al. demonstrated that the top prescription rankings in the United States included lisinopril, atorvastatin, and amoxicillin (Ottmar et al., 2010). As expected, the consumption of active compounds varies strongly from country to country.

Although sales data on certain pharmaceuticals apparently indicate significant consumption levels, their discharge load rankings can be lower than their sales data rankings because of low excretion efficiencies. For example,  $PEC_{inf}$  of pranlukast was 257.0  $\mu\text{g/L}$  with excretion efficiency of 86.6% (Down et al., 1974; Nakashima et al., 1993), indicating that pranlukast is the most prevalent pharmaceutical in wastewater influent. Although the yearly sale of rebamipide was 363.0 t, which is higher than that of iopamidol (309.9 t), the excretion efficiencies of rebamipide and iopamidol were 10% (Naito and


Yoshikawa, 2010) and 100% (Pharmaceuticals and Medical Devices Agency, Japan), respectively, meaning that the  $PEC_{inf}$  of rebamipide (2.6  $\mu\text{g/L}$ ) was considerably lower than that of iopamidol (22.5  $\mu\text{g/L}$ ). Based on their excretion efficiencies, the PECs of pranlukast, ethyl icosapentate, carbocysteine, metformin, iopamidol, salicylic acid, acyclovir, iohexol, levofloxacin, and povidone iodine would be expected to have extremely high values in wastewater influent ( $> 10 \mu\text{g/L}$ ), and 36 pharmaceuticals would be expected to have high concentrations in wastewater influent ( $> 1 \mu\text{g/L}$ ). Among these pharmaceuticals with high concentrations, analgesics/anti-inflammatories and antibiotics appear to be the predominant groups in wastewater influent. Furthermore, some specific pharmaceuticals, such as allopurinol, were predicted for the first time in Japan (1.8  $\mu\text{g/L}$ ). Although the PEC of metformin in wastewater influent was predicted to be 24.1  $\mu\text{g/L}$ , no study has yet evaluated its concentration in Japanese wastewater. In other studies, metformin was widely detected at a frequency of occurrence of 100% and an average concentration of 8.1  $\mu\text{g/L}$  (Burns et al., 2018); the order of magnitude of its PEC in Japanese wastewater was similar to those reported in other countries (Oosterhuis et al., 2013; Tisler and Zwiener, 2018; Yan et al., 2019). Even though a wide variety of pharmaceuticals can be found in wastewater influent, it should be noted that not all their concentrations can be determined. Thus, the present study has provided a list of pharmaceuticals that warrant further investigation due to their high PEC values.

### 3.3. Evaluation of PEC in wastewater effluent

Table S3 in Supplementary material and Fig. 3 show that removal efficiencies of pharmaceuticals in Japanese WWTPs predicted by the EPI suite are within the range of, or less than observed removal efficiencies, allowing for considerable scatter in the results. According to the criteria in Table 1, the accurate level could be  $0.5 < \text{ratio} < 2$ , and 19 compounds could be fit for the criteria in Fig. 3. The EPI suite adequately simulated the removal of biodegradable pharmaceuticals such as acetaminophen, naproxen, and ibuprofen (the ratios of their predicted removal efficiencies and observed removal efficiencies were 0.77, 1.91, and 1.16, respectively), which have high biodegradability and relatively weak sorption in WWTPs, as shown in previous studies (He et al., 2018; Min et al., 2018; Onesios et al., 2009; Tiwari et al., 2017). Estimated removals using the EPI suite were calculated from the biodegradability related to chemical structure and  $K_{oc}$  coefficients for sorption. From the perspective of chemical characteristics, the EPI suite performed better in estimating the removals of analgesics and hypolipidemic agents, such as acetaminophen, bezafibrate, naproxen, gemfibrozil, and ibuprofen (75.1%, 60.6%, 95.3%, 97.2%, and 94.9%, respectively).

Differences between reported and EPI estimated removal efficiencies were observed for antibiotics such as ciprofloxacin and clarithromycin; these antibiotics have poor biodegradability, but it has been previously found that they can be adsorbed in activated sludge (Min et al., 2018; Tiwari et al., 2017). In practice, it is difficult to predict accurately the sorption of pharmaceuticals in sludge, owing to factors such as pH in WWTPs (Ternes et al., 2004).

Discrepancies in removal efficiencies were observed by Verlicchi et al. (2012) who found that removal efficiencies in WWTPs were correlated to their characteristics, including biological reactor shape, operating conditions (solids retention time (SRT), hydraulic retention time (HRT), pH, redox conditions, etc.) and the water quality of the influent. Onesios et al. reported that removal of clarithromycin ranged from 0 to 54%, whereas the range of ofloxacin removal was from 23.8% to 94.0% (Onesios et al., 2009). Thus, in wastewater effluent, PEC calculations based on generalized data may be vulnerable to a high degree of inaccuracy because of different operating condition or wastewater composition (Choi et al., 2020). To compensate for these discrepancies, Coetsier et al. suggested adopting either the mean of a wide range of published data if available, or else considering an extreme



**Fig. 2.** Yearly sale loads and PECs in wastewater influent of pharmaceuticals by their classification (a), and the excretion efficiencies referring to the classification of pharmaceuticals (b).

scenario (Coetsier et al., 2009). Although the PEC could be overestimated, predicted removal efficiencies should be less than reported removal efficiencies. Turning to the extreme scenario concept, the results predicted by the EPI suite appear acceptable, as shown in Fig. 3, and so the EPI suite was applied herein to predict removal efficiencies.

After applying the predicted removal efficiencies and predicted concentrations in the influent (36 pharmaceuticals with high concentrations,  $> 1 \mu\text{g/L}$  as discussed above), the concentration of these pharmaceuticals in the effluent was predicted (Table S2 in Supplementary material), and Table S2 provides the full information of PECs in the influent and effluent of WWTPs. Among the selected pharmaceuticals, 26 pharmaceuticals were considered important in the effluent due to their high concentrations ( $> 1 \mu\text{g/L}$ ), including 6 pharmaceuticals with concentrations in excess of  $10 \mu\text{g/L}$ . Of these

pharmaceuticals, the PEC of pranlukast in wastewater effluent was the most significant ( $203.8 \mu\text{g/L}$ ) because of its low predicted removal efficiency by the EPI suite. Although the concentrations of several pharmaceuticals such as iopamidol and levofloxacin have been reported to be high in wastewater or receiving water in Japan (Azuma et al., 2018; Watanabe et al., 2016), the occurrence of other pharmaceuticals with high concentrations (i.e., povidone iodine, carbocysteine, and cefazolin) have not been reported in Japan previously, and these results provide a concerning list of pharmaceuticals that pose an environmental risk to aquatic environments. For those pharmaceuticals ( $> 1 \mu\text{g/L}$ ) not measured in Japan, such as allopurinol, its  $PEC_{inf}$  and  $PEC_{eff}$  in this study were 1750.10, and 436.47 ng/L, respectively. In other countries, the  $PEC_{inf}$  of allopurinol was reported to be 1000 ng/L (Sedlak and Pinkston, 2011) and 4360 ng/L (Lacorte et al., 2018); and




Fig. 3. Comparison between predicted (EPI suite) and measured (from open literature) removal efficiencies.

the  $MEC_{inf}$  was reported as 600 ng/L (Grünebaum, 2011) and 3000 ng/L (Khan and Ongerth, 2004), as well as that its  $MEC_{eff}$  was 2000 ng/L (Khan and Ongerth, 2004) and 1700 ng/L (Gómez-Canela et al., 2019). Based on above values, similar concentration behavior of allopurinol was found in Japan and other countries. Furthermore, for famotidine, its  $PEC_{inf}$  and  $PEC_{eff}$  in this study were 1268.22, and 989.47 ng/L, respectively; its  $MEC_{inf}$  was reported to be 10–210 ng/L (Ahmed et al., 2017) and  $273 \pm 164$  ng/L (Campos-Mañas et al., 2017); its  $MEC_{eff}$  was 132 ng/L with 84.0% of removal efficiency in membrane reactor (Dolar et al., 2012), and famotidine showed different influent concentration level in Japan from other countries. Therefore, the performance of pharmaceutical consumption can be evaluated by comparison of PEC or MEC in Japan and other countries.

At present, the EPI suite does not take into account the transformation and removal of pharmaceutical metabolites. From a risk assessment perspective, metabolites may be responsible for as much observed environmental toxicity as their parent compounds (Escher and Fenner, 2011). The EPI suite includes biodegradation and sorption in activated sludge but does not consider advanced treatment processes, such as ozonation, advanced oxidation process (AOP), and chlorination, which could lead to lower effluent concentrations.

### 3.4. Implication for environmental risk assessment

Environmental risk prioritization is important because it identifies the highest risk pharmaceuticals that warrant further investigation and monitoring (Guo et al., 2016). Evaluation of the PEC of pharmaceuticals and their PNEC calculated from the ECOSAR and KATE system showed that the PEC-to-PNEC ratios for 19 pharmaceuticals were above 0.1 (Table S2 in Supplementary material), indicating high toxicity in the aquatic environment, and 54 pharmaceuticals had ratios exceeding 0.01, indicating their toxicities should be evaluated in detail, including 19 pharmaceuticals with median toxicities (PEC-to-PNEC ratios above 0.1). It is worth noting that the environmental risks of several pharmaceuticals such as bezafibrate (0.074) and sulfamethoxazole (0.021) have been evaluated in previous Japanese studies (Komori et al., 2013), but the environmental risks of other pharmaceuticals, including tocoferol salt, teprenone, and azelnidipine, which were observed at high concentrations in Japanese wastewater effluent, have not previously been reported. The present study has provided a list of pharmaceuticals for which a comprehensive risk estimate is required. Fig. 4 classifies pharmaceuticals into four groups according to toxicity and concentration: (I) attention-worthy toxicity and attention-worthy concentration; (II) attention-worthy toxicity and negligible concentration; (III) negligible toxicity and negligible concentration; and (IV) negligible toxicity and attention-worthy concentration.




Fig. 4. PEC and environmental risk (ratio of PEC and PNEC) in wastewater effluent caused by the presence of pharmaceuticals.

and attention-worthy concentration. From the perspective of safety, the risks posed by pharmaceuticals in groups I, II, and IV need to be evaluated in the future. For pharmaceuticals in categories (I) and (II), in order to alleviate the environmental risk, advanced treatments are suggested for their effective removals, including ozonation for triclosan (Orhon et al., 2017), and ozonated microbubbles for bicalutamide (Azuma et al., 2019a,b).

In summary, the present sales-based prediction method has provided acceptable estimates of influent pharmaceutical concentrations. The resulting predictions indicate the extent to which previous environmental analyses have ignored several of the most potentially problematic pharmaceuticals, such as pranlukast and carbocysteine. The STP script in the EPI suite proved useful in evaluating the significant discharge of pharmaceuticals from WWTPs, and in highlighting important pharmaceuticals in an extreme scenario. In particular, the occurrence of several pharmaceuticals, such as metformin, is noteworthy and requires further investigation, because these drugs exhibit high effluent concentration levels and pose significant potential environmental risks.

Besides providing the prediction of pharmaceuticals in wastewater system with their environmental risks, the limitations of this study were presented. First, Besides the difference between local consumption and national consumption of pharmaceuticals, unknown sources of pharmaceuticals discharge were unable to be applied in this study. Second, wastewater composition may affect the transformation of pharmaceuticals, which was not investigated due to the lack of data in the literature (Choi et al., 2020). Third, for pharmaceuticals, the transformation of metabolites was not considered in this study, for example, deglucuronidation of phase-II metabolites can result in higher concentrations of the parent compound, with higher measured environmental concentrations (Gauderat et al., 2016; Gao et al., 2018; He et al., 2019).

## 4. Conclusions

The present study has demonstrated that sales data of pharmaceuticals in Japan can be used for the prediction of pharmaceuticals in wastewater influent. The main findings are summarized as follows:

- (1) According to reverse analysis of epidemiology for wastewater prediction, the PECs of 36 pharmaceuticals had high values in wastewater influent and so need further, detailed investigation. Pranlukast had the highest PEC in wastewater influent in Japan (257.0  $\mu\text{g/L}$ ).
- (2) By applying the EPI suite to the prediction of pharmaceutical removals from wastewater systems and considering the most extreme



scenario, it was predicted that pranlukast was of greatest concern in wastewater effluent in Japan because of its resistance to biodegradation and its high consumption in the Japanese market. Moreover, 9 pharmaceuticals in the effluent exhibited potentially high toxicity according to the PEC/PNEC ratio, and 54 pharmaceuticals exhibited some toxicity. Therefore, further study is needed to explore the toxicity of these.

Overall, these findings provide confidence in the use of PECs in prioritization exercises for pharmaceuticals. Furthermore, the results prove that reverse analysis of epidemiology can be used widely in the future to predict environmental risk posed by pharmaceutical discharges. Beyond Japan, the proposed method could be applied to prioritization of pharmaceutical monitoring activities and environmental risk predictions in other countries.

### CRedit authorship contribution statement

**Kai He:** Investigation, Formal analysis, Data curation, Writing - original draft. **Alistair G. Borthwick:** Data curation, Writing - review & editing. **Yingchao Lin:** Investigation, Formal analysis, Data curation. **Yueneng Li:** Formal analysis, Data curation. **Jie Fu:** Methodology, Writing - review & editing. **Yongjie Wong:** Formal analysis, Data curation. **Wen Liu:** Conceptualization, Methodology, Writing - review & editing, Supervision.

### Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Acknowledgment

Financial supports from the National Nature Science Foundation of China (NSFC) (No. 21906001 and No. 51721006) are greatly acknowledged. We also appreciated the supports from Japan Society for the Promotion of Science (No. 19K15122), Beijing Nova Program (Z19111000110000) and Opening Foundation of Ministry of Education Key Laboratory of Pollution Processes and Environmental Criteria (201901).

### Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.envint.2020.105690>.

### References

- Alder, A.C., Schaffner, C., Majewsky, M., Klasmeyer, J., Fenner, K., 2010. Fate of  $\beta$ -blocker human pharmaceuticals in surface water: comparison of measured and simulated concentrations in the Glatt Valley Watershed, Switzerland. *Water Res.* 44, 936–948.
- Ahmed, M.B., Zhou, J.L., Ngo, H.H., Guo, W., Thomaidis, N.S., Xu, J., 2017. Progress in the biological and chemical treatment technologies for emerging contaminant removal from wastewater: a critical review. *J. Hazard. Mater.* 323, 274–298.
- Azuma, T., Arima, N., Tsukada, A., Hirami, S., Matsuoka, R., Moriwake, R., Ishiuchi, H., Inoyama, T., Teranishi, Y., Yamaoka, M., Mino, Y., Hayashi, T., Fujita, Y., Masada, M., 2016. Detection of pharmaceuticals and phytochemicals together with their metabolites in hospital effluents in Japan, and their contribution to sewage treatment plant influents. *Sci. Total Environ.* 548–549, 189–197.
- Azuma, T., Nakada, N., Yamashita, N., Tanaka, H., 2015. Evaluation of concentrations of pharmaceuticals detected in sewage influents in Japan by using annual shipping and sales data. *Chemosphere* 138, 770–776.
- Azuma, T., Otomo, K., Kunitou, M., Shimizu, M., Hosomaru, K., Mikata, S., Ishida, M., Hisamatsu, K., Yunoki, A., Mino, Y., Hayashi, T., 2019a. Environmental fate of pharmaceutical compounds and antimicrobial-resistant bacteria in hospital effluents, and contributions to pollutant loads in the surface waters in Japan. *Sci. Total Environ.* 657, 476–484.
- Azuma, T., Otomo, K., Kunitou, M., Shimizu, M., Hosomaru, K., Mikata, S., Mino, Y., Hayashi, T., 2018. Performance and efficiency of removal of pharmaceutical

- compounds from hospital wastewater by lab-scale biological treatment system. *Environ. Sci. Pollut. Res.* 25, 14647–14655.
- Azuma, T., Otomo, K., Kunitou, M., Shimizu, M., Hosomaru, K., Mikata, S., Mino, Y., Hayashi, T., 2019b. Removal of pharmaceuticals in water by introduction of ozonated microbubbles. *Sep. Purif. Technol.* 212, 483–489.
- Benotti, M.J., Trenholm, R.A., Vanderford, B.J., Holady, J.C., Stanford, B.D., Snyder, S.A., 2008. Pharmaceuticals and endocrine disrupting compounds in US drinking water. *Environ. Sci. Technol.* 43, 597–603.
- Boxall, A.B., Rudd, M.A., Brooks, B.W., Caldwell, D.J., Choi, K., Hickmann, S., Innes, E., Ostapyk, K., Staveley, J.P., Verslycke, T., 2012. Pharmaceuticals and personal care products in the environment: what are the big questions? *Environ. Health Perspect.* 120, 1221–1229.
- Burns, E.E., Carter, L.J., Kolpin, D.W., Thomas-Oates, J., Boxall, A.B., 2018. Temporal and spatial variation in pharmaceutical concentrations in an urban river system. *Water Res.* 137, 72–85.
- Caldwell, D.J., D'Aco, V., Davidson, T., Kappler, K., Murray-Smith, R.J., Owen, S.F., Robinson, P.F., Simon-Hettich, B., Straub, J.O., Tell, J., 2019. Environmental risk assessment of metformin and its transformation product guanlyurea: II. Occurrence in surface waters of Europe and the United States and derivation of predicted no-effect concentrations. *Chemosphere* 216, 855–865.
- Campos-Mañás, M.C., Plaza-Bolaños, P., Sánchez-Pérez, J.A., Malato, S., Agüera, A., 2017. Fast determination of pesticides and other contaminants of emerging concern in treated wastewater using direct injection coupled to highly sensitive ultra-high performance liquid chromatography-tandem mass spectrometry. *J. Chromatogr. A* 1507, 84–94.
- Carballa, M., Omil, F., Lema, J.M., 2008. Comparison of predicted and measured concentrations of selected pharmaceuticals, fragrances and hormones in Spanish sewage. *Chemosphere* 72, 1118–1123.
- Choi, P.M., Li, J., Gao, J., O'Brien, J.W., Thomas, K.V., Thai, P.K., Jiang, G.M., Mueller, J.F., 2020. Considerations for assessing stability of wastewater-based epidemiology biomarkers using biofilm-free and sewer reactor tests. *Sci. Total Environ.* 709, 136228.
- Coetsier, C., Spinelli, S., Lin, L., Roig, B., Touraud, E., 2009. Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs? *Environ. Int.* 35, 787–792.
- Daughton, C.G., Ternes, T.A., 1999. Pharmaceuticals and personal care products in the environment: agents of subtle change? *Environ. Health Perspect.* 107, 907.
- Dave, R.A., Morris, M.E., 2016. A quantitative threshold for high/low extent of urinary excretion of compounds in humans. *Biopharm. Drug Dispos.* 37, 287–309.
- Dolar, D., Gros, M., Rodríguez-Mozaz, S., Moreno, J., Comas, J., Rodríguez-Roda, I., Barceló, D., 2012. Removal of emerging contaminants from municipal wastewater with an integrated membrane system, MBR-RO. *J. Hazard. Mater.* 239, 64–69.
- Down, W., Chasseaud, L., Grundy, R., 1974. Biotransformation of isosorbide dinitrate in humans. *J. Pharm. Sci.* 63, 1147–1149.
- Du, B., Price, A.E., Scott, W.C., Kristofco, L.A., Ramirez, A.J., Chambliss, C.K., Yelderman, J.C., Brooks, B.W., 2014. Comparison of contaminants of emerging concern removal, discharge, and water quality hazards among centralized and on-site wastewater treatment system effluents receiving common wastewater influent. *Sci. Total Environ.* 466, 976–984.
- Ebele, A.J., Abdallah, M.A.-E., Harrad, S., 2017. Pharmaceuticals and personal care products (PPCPs) in the freshwater aquatic environment. *Emerg. Contam.* 3, 1–16.
- Escher, B.I., Fenner, K., 2011. Recent advances in environmental risk assessment of transformation products. *Environ. Sci. Technol.* 45, 3835–3847.
- Fukutomi, Y., Taniguchi, M., Watanabe, J., Nakamura, H., Komase, Y., Ohta, K., Akasawa, A., Nakagawa, T., Miyamoto, T., Akiyama, K., 2011. Time trend in the prevalence of adult asthma in Japan: findings from population-based surveys in Fujiyama City in 1985, 1999, and 2006. *Allergol. Int.* 60, 443–448.
- Furuhashi, A., Hasunuma, K., Aoki, Y., Yoshioka, Y., Shiraishi, H., 2011. Application of chemical reaction mechanistic domains to an ecotoxicity QSAR model, the KASHINhou Tool for Ecotoxicity (KATE). *SAR QSAR Environ. Res.* 22, 505–523.
- Furuta, S., Akagawa, N., Kamada, E., Hiya, A., Kawabata, Y., Kowata, N., Inaba, A., Matthews, A., Hall, M., Kurimoto, T., 2002. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. *Br. J. Clin. Pharmacol.* 54, 295–303.
- Gao, J., Li, J., Jiang, G., Yuan, Z., Eaglesham, G., Covaci, A., Mueller, J.F., Thai, P.K., 2018. Stability of alcohol and tobacco consumption biomarkers in a real rising main sewer. *Water Res.* 138, 19–26.
- Gauderat, G., Picard-Hagen, N., Toutain, P. L., Corbel, T., Vigiúé, C., Puel, S., Marlène Z. Lacroix, M.Z., Mindeguia, P., Bousquet-Melou, A., Gayraud, V., 2016. Bisphenol A glucuronide deconjugation is a determining factor of fetal exposure to bisphenol A. *Environ. Int.* 86, 52–59.
- Gómez-Canela, C., Pueyo, V., Barata, C., Lacorte, S., Marcé, R.M., 2019. Development of predicted environmental concentrations to prioritize the occurrence of pharmaceuticals in rivers from Catalonia. *Sci. Total Environ.* 666, 57–67.
- Green, C., Brian, J., Kanda, R., Scholze, M., Williams, R., Jobling, S., 2015. Environmental concentrations of anti-androgenic pharmaceuticals do not impact sexual disruption in fish alone or in combination with steroid oestrogens. *Aquat. Toxicol.* 160, 117–127.
- Gregory, W., James, O., Turner, I., Meese, C., Idle, J., 1993. Re-evaluation of the metabolism of carbocysteine in a British white population. *Pharmacogenetics.* 3, 270–274.
- Grünebaum, T.P., 2011. Schlussbericht Phase 1: elimination von Arzneimittelrückständen in kommunalen Kläranlagen, Elimination von Arzneimitteln und organischen Spurenstoffen: Entwicklung von Konzeptionen und innovativen, kostengünstigen Reinigungsverfahren, LANUV NRW.
- Guerra, P., Kim, M., Shah, A., Alaei, M., Smyth, S., 2014. Occurrence and fate of antibiotic, analgesic/anti-inflammatory, and antifungal compounds in five wastewater treatment processes. *Sci. Total Environ.* 473, 235–243.

- Guo, J., Sinclair, C.J., Selby, K., Boxall, A.B., 2016. Toxicological and ecotoxicological risk-based prioritization of pharmaceuticals in the natural environment. *Environ. Toxicol. Chem.* 35, 1550–1559.
- Hanamoto, S., Nakada, N., Yamashita, N., Tanaka, H., 2018. Source estimation of pharmaceuticals based on catchment population and in-stream attenuation in Yodo River watershed, Japan. *Sci. Total Environ.* 615, 964–971.
- He, K., Asada, Y., Echigo, S., Itoh, S., 2018. Biodegradation of pharmaceuticals and personal care products in the sequential combination of activated sludge treatment and soil aquifer treatment. *Environ. Technol.* 1–11.
- He, K., Yonetani, T., Asada, Y., Echigo, S., Itoh, S., 2019. Simultaneous determination of carbamazepine-N-glucuronide and carbamazepine phase I metabolites in the wastewater by liquid chromatography-tandem mass spectrometry. *Microchem. J.* 145, 1191–1198.
- Huschek, G., Hansen, P., Maurer, H., Krengel, D., Kayser, A., 2004. Environmental risk assessment of medicinal products for human use according to European commission recommendations. *Environ. Toxicol.* 19, 226–240.
- Ishiura, Y., Fujimura, M., Yamamori, C., Nobata, K., Myou, S., Kurashima, K., Michishita, Y., Takegoshi, T., 2003. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. *Brit. J. Clin. Pharmacol.* 55, 504–510.
- Japan Pharmaceutical Information Center, 2004. iyakuSearch (accessed June 2019). <https://database.jpac.or.jp/is/top/index.jsp>.
- Japan Sewage Works Association, 2016. Management of Wastewater in Japan (accessed by 2019). <http://gcus.jp/wp/wp-content/uploads/2017/03/da25d58e311828646b563677c900b90c.pdf>.
- Japan Sewage Works Association, 2019. Percentage of sewered population in Japan (accessed June 2019). <http://www.jswwa.jp/sewage/qa/rate/>.
- Jones, O., Voulvoulis, N., Lester, J., 2002. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. *Water Res.* 36, 5013–5022.
- Jones, O.A., Lester, J.N., Voulvoulis, N., 2005. Pharmaceuticals: a threat to drinking water? *Trends Biotechnol.* 23, 163–167.
- Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., Morishima, K., 2016. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucl. Acids Res.* 45, D353–D361.
- Orhon, K.B., Orhon, A.K., Dilek, F.B., Yetis, U., 2017. Triclosan removal from surface water by ozonation-Kinetics and by-products formation. *J. Environ. Manage.* 204, 327–336.
- Kanagawa Sewerage Work Foundation, 2019. Sewerage Q&A (accessed by 2019) (in Japanese). <http://www.kanagawa-swf.or.jp/shikumi/shikumi-q-and-a-iltupan.htm>.
- Kim, I., Yamashita, N., Tanaka, H., 2009. Performance of UV and UV/H<sub>2</sub>O<sub>2</sub> processes for the removal of pharmaceuticals detected in secondary effluent of a sewage treatment plant in Japan. *J. Hazard. Mater.* 166, 1134–1140.
- Khan, S.J., Ongerth, J.E., 2004. Modelling of pharmaceutical residues in Australian sewage by quantities of use and fugacity calculations. *Chemosphere* 54 (3), 355–367.
- Kobayashi, Y., Okuda, T., Yamashita, N., Tanaka, H., Tanaka, S., Fujii, S., Konishi, C., Houwa, I., 2006. The occurrence of pharmaceuticals during advanced wastewater treatment. *Environ. Eng. Res.* 43, 65–72.
- Komori, K., Suzuki, Y., Minamiyama, M., Harada, A., 2013. Occurrence of selected pharmaceuticals in river water in Japan and assessment of their environmental risk. *Environ. Monit. Assess.* 185, 4529–4536.
- Kostich, M.S., Batt, A.L., Lazorchak, J.M., 2014. Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation. *Environ. Pollut.* 184, 354–359.
- Lacorte, S., Luis, S., Gómez-Canela, C., Sala-Comorera, T., Courtier, A., Roig, B., Oliveira-Brett, A.M., Joannis-Cassan, C., Aragónés, J.I., Poggio, L., Noguera, T., Lima, L., Barata, C., Calas-Blanchard, C., 2018. Pharmaceuticals released from senior residences: occurrence and risk evaluation. *Environ. Sci. Pollut. Res. Int.* 25 (7), 6095–6106.
- Li, Y., Zhang, L., Liu, X., Ding, J., 2019. Ranking and prioritizing pharmaceuticals in the aquatic environment of China. *Sci. Total Environ.* 658, 333–342.
- Liu, J.L., Wong, M.H., 2013. Pharmaceuticals and personal care products (PPCPs): a review on environmental contamination in China. *Environ. Int.* 59, 208–224.
- Lu, Z., Smyth, S.A., De Silva, A.O., 2019. Distribution and fate of synthetic phenolic antioxidants in various wastewater treatment processes in Canada. *Chemosphere* 219, 826–835.
- Lu, Z., Smyth, S.A., Peart, T.E., De Silva, A.O., 2017. Occurrence and fate of substituted diphenylamine antioxidants and benzotriazole UV stabilizers in various Canadian wastewater treatment processes. *Water Res.* 124, 158–166.
- Ma, R., Wang, B., Lu, S., Zhang, Y., Yin, L., Huang, J., Deng, S., Wang, Y., Yu, G., 2016. Characterization of pharmaceutically active compounds in Dongting Lake, China: Occurrence, chiral profiling and environmental risk. *Sci. Total Environ.* 557–558, 268–275.
- Mankes, R.F., Silver, C.D., 2013. Quantitative study of controlled substance bedside wasting, disposal and evaluation of potential ecologic effects. *Sci. Total Environ.* 444, 298–310.
- Mehrabad, J.T., Aghazadeh, M., Maragheh, M.G., Ganjali, M.R., Norouzi, P., 2016.  $\alpha$ -Co(OH)<sub>2</sub> nanoplates with excellent supercapacitive performance: Electrochemical preparation and characterization. *Mater. Lett.* 184, 223–226.
- Melnikov, F., Kostal, J., Voutchkova-Kostal, A., Zimmerman, J.B., Anastas, P.T., 2016. Assessment of predictive models for estimating the acute aquatic toxicity of organic chemicals. *Green Chem.* 18, 4432–4445.
- Metcalfe, C., Alder, A., Halling-Sørensen, B., Krogh, K., Fenner, K., Larsbo, M., Straub, J., Ternes, T., Topp, E., Lapen, D., 2008. Exposure assessment methods for veterinary and human-use medicines in the environment: PEC vs. MEC comparisons. In: Kümmerer, K. (Eds.), *Pharmaceuticals in the Environment*. Springer, Berlin, Heidelberg.
- Min, X., Li, W., Wei, Z., Spinney, R., Dionysiou, D.D., Seo, Y., Tang, C.-J., Li, Q., Xiao, R., 2018. Sorption and biodegradation of pharmaceuticals in aerobic activated sludge system: A combined experimental and theoretical mechanistic study. *Chem. Eng. J.* 342, 211–219.
- Ministry of Economy Trade and Industry, Japan, 2010. Discharge amount from wastewater treatment facilities (accessed June 2019). [http://www.meti.go.jp/policy/chemical\\_management/law/prtr/h21kohyo/todokedegai\\_haisyutsu/syousai/22.pdf](http://www.meti.go.jp/policy/chemical_management/law/prtr/h21kohyo/todokedegai_haisyutsu/syousai/22.pdf).
- Ministry of Health, Labour and Welfare, Japan, 2018. Japanese Annual Report on Pharmaceutical Industries (accessed June 2019). [https://www.e-stat.go.jp/stat-search/files?page=1&toukei=00450151&result\\_page=1](https://www.e-stat.go.jp/stat-search/files?page=1&toukei=00450151&result_page=1).
- Mitchell, S.M., Ullman, J.L., Teel, A.L., Watts, R.J., 2014. pH and temperature effects on the hydrolysis of three  $\beta$ -lactam antibiotics: Ampicillin, cefalotin and cefoxitin. *Sci. Total Environ.* 466, 547–555.
- Morasch, B., Bonvin, F., Reiser, H., Grandjean, D., De Alencastro, L.F., Perazzolo, C., Chèvre, N., Kohn, T., 2010. Occurrence and fate of micropollutants in the Vidy Bay of Lake Geneva, Switzerland. Part II: micropollutant removal between wastewater and raw drinking water. *Environ. Toxicol. Chem.* 29, 1658–1668.
- Naito, Y., Yoshikawa, T., 2010. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. *Expert Rev. Gastroenterol. Hepatol.* 4, 261–270.
- Nakada, N., Shinohara, H., Murata, A., Kiri, K., Managaki, S., Sato, N., Takada, H., 2007. Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. *Water Res.* 41, 4373–4382.
- Nakashima, M., Kanamaru, M., Tuematsu, T., Tsubokura, S., 1993. A phase I clinical study of a leukotriene C<sub>4</sub>, D<sub>4</sub>, and E<sub>4</sub> receptor antagonist; ONO-1078 in healthy volunteers. *J. Clin. Therap. Med.* 9, 3–29 (in Japanese).
- Narumiya, M., Okuda, T., Nakada, N., Yamashita, N., Tanaka, H., Sato, K., Sueoka, M., Oiwa, T., 2009. Occurrence and fate of pharmaceuticals and personal care products during wastewater treatments. *Environ. Eng. Res.* 46, 175 (in Japanese).
- National Information Program on Antibiotics, 2016. Antibiotic Drugs Clindamycin (accessed June 2019). <http://www.antibiotics-info.org/clindamycin.html>.
- Ogawa, H., 2006. Domestic wastewater treatment by johkasou systems in Japan. [https://www.env.go.jp/recycle/3r/en/asia/02\\_06/01.pdf](https://www.env.go.jp/recycle/3r/en/asia/02_06/01.pdf) (accessed June 2019).
- Onesios, K.M., Jim, T.Y., Bouwer, E.J., 2009. Biodegradation and removal of pharmaceuticals and personal care products in treatment systems: a review. *Biodegradation* 20, 441–466.
- Ong, T.T., Blanch, E.W., Jones, O.A., 2018. Predicted environmental concentration and fate of the top 10 most dispensed Australian prescription pharmaceuticals. *Environ. Sci. Pollut. Res.* 25, 10966–10976.
- Oosterhuis, M., Sacher, F., ter Laak, T.L., 2013. Prediction of concentration levels of metformin and other high consumption pharmaceuticals in wastewater and regional surface water based on sales data. *Sci. Total Environ.* 442, 380–388.
- Ort, C., Hollender, J., Schaerer, M., Siegrist, H., 2009. Model-based evaluation of reduction strategies for micropollutants from wastewater treatment plants in complex river networks. *Environ. Sci. Technol.* 43, 3214–3220.
- Ort, C., Lawrence, M.G., Rieckermann, J., Joss, A., 2010. Sampling for pharmaceuticals and personal care products (PPCPs) and illicit drugs in wastewater systems: are our conclusions valid? A critical review. *Environ. Sci. Technol.* 44, 6024–6035.
- Ottmar, K.J., Colosi, L.M., Smith, J.A., 2010. Development and application of a model to estimate wastewater treatment plant prescription pharmaceutical influent loadings and concentrations. *Bull. Environ. Contam. Toxicol.* 84, 507–512.
- Petrović, M., Hernando, M.D., Díaz-Cruz, M.S., Barceló, D., 2005. Liquid chromatography-tandem mass spectrometry for the analysis of pharmaceutical residues in environmental samples: a review. *J. Chromatogr. A* 1067, 1–14.
- Pharmaceuticals and Medical Devices Agency, 2019. The interview form for pharmaceuticals (accessed June 2019). [http://www.info.pmda.go.jp/psearch/html/menu\\_tenpu\\_base.html](http://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html).
- Phung, D., Mueller, J., Lai, F.Y., O'Brien, J., Dang, N., Morawska, L., Thai, P.K., 2017. Can wastewater-based epidemiology be used to evaluate the health impact of temperature?—An exploratory study in an Australian population. *Environ. Res.* 156, 113–119.
- Rhee, S.J., Shin, K.H., Cha, Y.J., Kim, J.R., Oh, D.S., Cho, J.Y., Yu, K.S., Jang, I.J., Chung, J.Y., Lim, K.S., 2013. Pharmacokinetic characteristics of cefcapene pivoxil hydrochloride after single oral administration in healthy Korean subjects. *J. Korean Soc. Clin. Pharmacol. Ther.* 21, 104–112 (in Korean).
- Ruhoy, I.S., Daughton, C.G., 2008. Beyond the medicine cabinet: An analysis of where and why medications accumulate. *Environ. Int.* 34, 1157–1169.
- Sakashita, M., Yamaguchi, T., Miyazaki, H., Sekine, Y., Nomiya, T., Tanaka, S., Miwa, T., Harasawa, S., 1993. Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. *Arzneim.-Forsch.* 43, 867–872.
- Sanderson, H., Thomsen, M., 2007. Ecotoxicological Quantitative Structure-Activity Relationships for Pharmaceuticals. *Bull. Environ. Contam. Toxicol.* 79, 331–335.
- Scheurer, M., Sacher, F., Brauch, H.-J., 2009. Occurrence of the antidiabetic drug metformin in sewage and surface waters in Germany. *J. Environ. Monitor.* 11, 1608–1613.
- Schwarzenbach, R.P., Escher, B.I., Fenner, K., Hofstetter, T.B., Johnson, C.A., Von Gunten, U., Wehrli, B., 2006. The challenge of micropollutants in aquatic systems. *Science* 313, 1072–1077.
- Sedlak, D.L., Pinkston, K.E., 2011. Factors affecting the concentrations of pharmaceuticals released to the aquatic environment. *J. Contemp. Water Res. Educ.* 56–64.
- Singh, R.R., Angeles, L.F., Butryn, D.M., Metch, J.W., Garner, E., Vikesland, P.J., Aga, D.S., 2019. Towards a harmonized method for the global reconnaissance of multi-class antimicrobials and other pharmaceuticals in wastewater and receiving surface waters. *Environ. Int.* 124, 361–369.
- Spratto, G.R., Woods, A.L., 2010. *Delmar Nurse's Drug Handbook 2011: Special 20 Year Anniversary*, Delmar Cengage Learning, New York.

- Statistics Bureau of Japan, 2017. Result of the Population Estimates (accessed by 2019). <https://www.stat.go.jp/data/jinsui/new.html>.
- Suissa, S., Ernst, P., 2003. Use of anti-inflammatory therapy and asthma mortality in Japan. *Eur. Respir. J.* 21, 101–104.
- Suzuki, T., 2012. Occurrence of selected human pharmaceuticals and prediction of their environmental concentrations in the aquatic environment. *Ann. Rep. Tokyo Metr. Inst. Pub. Health* 63, 69–81.
- Tauxe-Wuersch, A., De Alencastro, L.F., Grandjean, D., Tarradellas, J., 2005. Occurrence of several acidic drugs in sewage treatment plants in Switzerland and risk assessment. *Water Res.* 39, 1761–1772.
- ter Laak, T.L., van der Aa, M., Houtman, C.J., Stoks, P.G., van Wezel, A.P., 2010. Relating environmental concentrations of pharmaceuticals to consumption: a mass balance approach for the river Rhine. *Environ. Int.* 36, 403–409.
- Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., Egusa, G., Hiro, T., Hirobe, K., Iida, M., 2013. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version. *J. Atheroscler. Thromb.* 15792.
- Ternes, T.A., Herrmann, N., Bonerz, M., Knacker, T., Siegrist, H., Joss, A., 2004. A rapid method to measure the solid–water distribution coefficient (Kd) for pharmaceuticals and musk fragrances in sewage sludge. *Water Res.* 38, 4075–4084.
- Thomas, K.V., Reid, M.J., 2011. What else can the analysis of sewage for urinary biomarkers reveal about communities? *Environ. Sci. Technol.* 45, 7611–7612.
- Tisler, S., Zwiener, C., 2018. Formation and occurrence of transformation products of metformin in wastewater and surface water. *Sci. Total. Environ.* 628–629, 1121–1129.
- Tiwari, B., Sellamuthu, B., Ouarda, Y., Drogui, P., Tyagi, R.D., Buelna, G., 2017. Review on fate and mechanism of removal of pharmaceutical pollutants from wastewater using biological approach. *Bioresour. Technol.* 224, 1–12.
- Verlicchi, P., Al Aukidy, M., Jelic, A., Petrović, M., Barceló, D., 2014. Comparison of measured and predicted concentrations of selected pharmaceuticals in wastewater and surface water: a case study of a catchment area in the Po Valley (Italy). *Sci. Total. Environ.* 470, 844–854.
- Verlicchi, P., Al Aukidy, M., Zambello, E., 2012. Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment—a review. *Sci. Total. Environ.* 429, 123–155.
- Wang, J., Ding, L., Du, X.L., Tang, L.C., Wang, Y.Q., 2012. Determination of Ecabet and Bismuth in human urine and study on their urinary excretion profiles. *J. Chin. Pharm. Sci.* 47, 825–829.
- Watanabe, Y., Bach, L.T., Van Dinh, P., Prudente, M., Aguja, S., Phay, N., Nakata, H., 2016. Ubiquitous detection of artificial sweeteners and iodinated X-ray contrast media in aquatic environmental and wastewater treatment plant samples from Vietnam, The Philippines, and Myanmar. *Arch. Environ. Contam. Toxicol.* 70, 671–681.
- Winker, M., Tettenborn, F., Faika, D., Gulyas, H., Otterpohl, R., 2008. Comparison of analytical and theoretical pharmaceutical concentrations in human urine in Germany. *Water Res.* 42, 3633–3640.
- Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., Wilson, M., 2017. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res.* 46, D1074–D1082.
- Yan, J.H., Xiao, Y., Tan, D.Q., Shao, X.T., Wang, Z., Wang, D.G., 2019. Wastewater analysis reveals spatial pattern in consumption of anti-diabetes drug metformin in China. *Chemosphere* 222, 688–695.
- You, L., Nguyen, V.T., Pal, A., Chen, H., He, Y., Reinhard, M., Gin, K.Y.-H., 2015. Investigation of pharmaceuticals, personal care products and endocrine disrupting chemicals in a tropical urban catchment and the influence of environmental factors. *Sci. Total. Environ.* 536, 955–963.
- Zeng, H., Fu, X., Liang, Y., Qin, L., Mo, L., 2018. Risk assessment of an organochlorine pesticide mixture in the surface waters of Qingshitan Reservoir in Southwest China. *RSC Adv.* 8, 17797–17805.
- Zhou, S., Di Paolo, C., Wu, X., Shao, Y., Seiler, T.B., Hollert, H., 2019. Optimization of screening-level risk assessment and priority selection of emerging pollutants—The case of pharmaceuticals in European surface waters. *Environ. Int.* 128, 1–10.
- Zwiener, C., 2007. Occurrence and analysis of pharmaceuticals and their transformation products in drinking water treatment. *Anal. Bioanal. Chem.* 387, 1159–1162.